Brainstorm Cell upgraded by Maxim Group
$BCLI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Maxim Group upgraded Brainstorm Cell from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicineNEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehrig Day and reflects on the courage and resilience of those living with the disease, the publication highlights the growing need for regulatory approaches that keep pace with advances in science and the u
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol AssessmentNEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately. Mr. Pitts is a globally recognized expert in healthcare policy, regulatory science, and U.S. Food and Drug Administration (FDA) governance. He previously served as A
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE TrialNEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing:The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. Investors will also receive 120% warrant coverage with an exercise price of $1.45 per share and a five-year term from the date of issuance. Two of t
EFFECT - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
3 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
Maxim Group upgraded Brainstorm Cell from Hold to Buy
Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol AssessmentNEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately. Mr. Pitts is a globally recognized expert in healthcare policy, regulatory science, and U.S. Food and Drug Administration (FDA) governance. He previously served as A
Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024. Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm. He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin
NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confir
Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call. Following the
SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)